🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsRetatrutide and blood pressure — need advice Page 7

Retatrutide and blood pressure — need advice

Dr.RenalNash Wed, Jun 4, 2025 at 8:12 PM 43 replies 2,143 viewsPage 7 of 9
MeganSA_TX
Member
634
2,890
Jun 2024
San Antonio, TX
Jun 12, 2025 at 12:31 AM#31
dan_philly said:
6 month update on cardiovascular risk: down 53 lbs, off blood pressure meds, A1C normalized.
dan_philly said:
...we don't know the long-term effects of cardiovascular risk...

This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.

However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.

Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.

Last edited: Jun 12, 2025 at 2:31 AM
41 14PharmD_Rodriguez, julia.endo, JessicaM_2024 and 38 others
Reply Quote Save Share Report
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Jun 12, 2025 at 12:36 PM#32
dan_philly said:
6 month update on cardiovascular risk: down 53 lbs, off blood pressure meds, A1C normalized.

That reframing is the part I needed. I will report back once I have actually tried it.

42 15kim_atl_prep, sarah_TO, wendy_avl and 39 others
Reply Quote Save Share Report
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Jun 13, 2025 at 12:41 AM#33

Adding the clinical framing, because it changes how the question reads.

Dizziness and cardiovascular risk: I was lightheaded for the first 3 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

Last edited: Jun 13, 2025 at 1:41 AM
43 16tampaLisa73, KarenAZ_mom, zoe_NC and 40 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Jun 13, 2025 at 12:45 PM#34
Dr.ObesityLA said:
Dizziness and cardiovascular risk: I was lightheaded for the first 3 weeks.

This matches mine closely enough to be worth saying so out loud.

Last edited: Jun 13, 2025 at 3:45 PM
44 17LarryQC_SD, wanda_boise, NurseAsh_DET and 41 others
Reply Quote Save Share Report
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Jun 14, 2025 at 12:49 AM#35
Dr.ObesityLA said:
Dizziness and cardiovascular risk: I was lightheaded for the first 3 weeks.

CRP reduction on cardiovascular risk — this is the lab result that excites me most:

Baseline hsCRP: 11.0 mg/L (high cardiovascular risk)
Month 6 hsCRP: 3.5 mg/L (moderate risk)
Month 12 hsCRP: 0.4 mg/L (low risk)

This level of inflammatory marker reduction is comparable to what you'd see with statin therapy. Combined with the weight loss, my 10-year ASCVD risk score dropped from 18% to 6%. My cardiologist is genuinely impressed.

45 18MounjBrad, nick_newbie, DadBodDave and 42 others
Reply Quote Save Share Report

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register